Infrared light-absorbing gold/gold sulfide nanoparticles induce cell death in esophageal adenocarcinoma
Received 18 August 2012
Accepted for publication 4 October 2012
Published 18 June 2013 Volume 2013:8(1) Pages 2153—2161
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Yan Li,1 Andre M Gobin,2 Gerald W Dryden,3 Xinqin Kang,1 Deyi Xiao,1 Su Ping Li,1 Guandong Zhang,2 Robert CG Martin1
1Department of Surgery, 2Department of Bioengineering, 3Division of Medicine, University of Louisville School of Medicine, Louisville, KY, USA
Abstract: Gold nanoparticles and near infrared-absorbing light are each innocuous to tissue but when combined can destroy malignant tissue while leaving healthy tissue unharmed. This study investigated the feasibility of photothermal ablation therapy for esophageal adenocarcinoma using chitosan-coated gold/gold sulfide (CS-GGS) nanoparticles. A rat esophagoduodenal anastomosis model was used for the in vivo ablation study, and three human esophageal cell lines were used to study the response of cancer cells and benign cells to near infrared light after treatment with CS-GGS. The results indicate that both cancerous tissue and cancer cells took up more gold nanoparticles and were completely ablated after exposure to near infrared light. The benign tissue and noncancerous cells showed less uptake of these nanoparticles, and remained viable after exposure to near infrared light. CS-GGS nanoparticles could provide an optimal endoluminal therapeutic option for near infrared light ablation of esophageal cancer.
Keywords: carcinoma, gold nanoparticles, ablation, near infrared, chitosan, drug uptake, cancer
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.